Posted by Michael Wonder on 16 Feb 2025
European Commission approves Egetis’ Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency
13 February 2025 - Egetis Therapeutics today announced that the European Commission has approved Emcitate (tiratricol) for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency.
Emcitate is the first and only medicine authorised in the European Union to treat MCT8 deficiency.
